<DOC>
	<DOCNO>NCT02400255</DOCNO>
	<brief_summary>This single-arm , Phase II study crenolanib maintenance AML patient FLT3 mutation achieve complete remission ( CR ) allogeneic stem cell transplantation . Oral crenolanib administer daily post-transplant two year .</brief_summary>
	<brief_title>Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation FLT3-positive Acute Myeloid Leukemia Patients</brief_title>
	<detailed_description>There two patient subgroup : 1 ) complete remission ( CR ) time transplant , 2 ) complete remission ( NCR ) time transplant . Start crenolanib therapy 100 mg TID intend early time sooner 30 day later 90 day allogeneic stem cell transplantation . Patients may take crenolanib continuously 728 day one criterion study discontinuation fulfil .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Crenolanib</mesh_term>
	<criteria>1 . History AML accord World Health Organization ( WHO ) classification 2 . First allogeneic hematopoietic stem cell transplantation ( HSCT ) use myeloablative conditioning ( MAC ) , nonmyeloablative ( NMA ) , reducedintensity conditioning ( RIC ) preparative regimen . 3 . FLT3ITD FLT3D835 positive disease time disease course . 4 . Hematopoietic stem cell source either peripheral blood , bone marrow cord blood . 5 . Donor source match related , unrelated , haploidentical donor cord blood . 6 . At time allogeneic HSCT : 1 . No 1 antigen mismatch HLAA , B , C , DRB1 DQB1 locus unrelated donor peripheral blood bone marrow hematopoietic stem cell source ; 2 . Bone marrow blast ≤ 10 % 7 . No sooner 45 day later 90 day allogeneic HSCT . 8 . Posttransplant bone marrow blast count ≤ 5 % confirm standard care bone marrow biopsy perform posttransplant ( least 30 day posttransplant ) . 9 . Evidence donor engraftment define institutional standard T cell chimerism &gt; 50 % . 10 . Adequate engraftment within 7 day prior start study therapy : ANC ≥ 1.0 x 109/L without daily use myeloid growth factor ; platelet ≥ 25 x 109/L without platelet transfusion within 1 week 11 . Nonhematological toxicity ≤ Grade 2 12 . Serum creatinine ≤ 1.5 × ULN OR creatinine clearance ≥ 50mL/min/1.73 m2 subject creatinine level institutional normal 13 . Adequate liver function serum AST , ALT bilirubin within normal range time crenolanib commencement 14 . Acute graftversushost disease ( GVHD ) ≤ Grade 1 , either sign chronic GVHD mild chronic GVHD grade limited disease 15 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 16 . Age ≥ 18 year capacity give write informed consent 17 . Nonpregnant nonnursing woman childbearing potential must negative serum urine pregnancy test ( `` Women childbearing potential '' define sexually active mature woman undergone hysterectomy menses time precede 24 consecutive month ) 18 . Women childbearing potential men must agree use adequate contraception prior study entry , duration study participation 90 day follow completion therapy 1 . Active GVHD grade ≥ 2 2 . Concurrent use corticosteroid equivalent prednisone dose &gt; 0.5 mg/kg 3 . Active and/or untreated central nervous system ( CNS ) leukemia 4 . Concomitant therapy treatment control leukemia . 5 . Use follow transplantation prior start study therapy : 1 . Chemotherapeutic agent therapy AML ( note prophylactic use agent allow study , e.g. , methotrexate GVHD ) 2 . Investigational agents/therapies 3 . Azacitidine , decitabine demethylating agent 4 . Lenalidomide , thalidomide pomalidomide 6 . Uncontrolled infection 7 . Known positive human immunodeficiency virus ( HIV ) ; active hepatitis B ( HBV ) hepatitis C ( HCV ) infection 8 . Significant cardiac disease ( New York Heart Association class III IV ) unstable angina despite medication 9 . Pregnant breastfeed 10 . Receipt investigational agent within 5 halflives last dose investigational agent 11 . Prior treatment crenolanib progression treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>